YM Bio's tesmilifene trial gets IDSMB OK

3 September 2006

Canadian drug developer YM BioSciences says that the independent data safety monitoring board reviewing a Phase III trial of its drug tesmilifene in breast cancer has recommended that it continue as planned. The IDSMB reached the decision following its second planned safety and efficacy analysis.

The study, which completed enrollment of 723 patients in September 2005, compares the survival time achieved by metastatic and/or recurrent breast cancer patients treated with combined tesmilifene and epirubicin/cyclophosphamide with those who receive only epirubicin/cyclophosphamide. The firm added that the drug is also under assessment in a separate study in combination with French drug major Sanofi-Aventis' Taxotere (docetaxel).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.